Targeting a protein to reduce kidney damage in chronic kidney disease.
Controlling renal oxidative stress in CKD via targeting FGF23 bioactivity
['FUNDING_OTHER'] · JACKSON LABORATORY · NIH-10910933
This study is looking at how a protein called FGF23 might help protect your kidneys from damage caused by stress, which is important for people with chronic kidney disease, and it hopes to find new ways to improve treatments for better health outcomes.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JACKSON LABORATORY (nih funded) |
| Locations | 1 site (BAR HARBOR, UNITED STATES) |
| Trial ID | NIH-10910933 on ClinicalTrials.gov |
What this research studies
This research investigates how controlling the activity of a protein called FGF23 can help manage oxidative stress in the kidneys, which is a significant factor in the progression of chronic kidney disease (CKD). The approach involves identifying new biological pathways that could be targeted to slow down or halt the deterioration of kidney function. By utilizing advanced techniques in molecular biology and bioinformatics, the research aims to translate these findings into potential therapies that could improve patient outcomes. Patients may benefit from new treatment strategies that arise from this work.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with chronic kidney disease who are experiencing oxidative stress-related complications.
Not a fit: Patients with acute kidney injury or those without chronic kidney disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that slow the progression of chronic kidney disease and improve kidney health.
How similar studies have performed: Previous research has shown promise in targeting oxidative stress pathways in kidney disease, suggesting that this approach could be effective.
Where this research is happening
BAR HARBOR, UNITED STATES
- JACKSON LABORATORY — BAR HARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: AGORO, RAFIOU — JACKSON LABORATORY
- Study coordinator: AGORO, RAFIOU
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.